GLP-1 Agonists Weight Loss Dual GIP/GLP-1 Agonists Multiple Incretin Agonists Gastrointestinal Peptides Under research

Survodutide

Also known as: BI 456906

Survodutide is a novel investigational dual agonist that simultaneously activates GLP-1 and Glucagon (GCG) receptors. Unlike Tirzepatide, which combines GLP-1 with GIP, Survodutide introduces the glucagon component, which has a profound impact on increasing basal metabolism and direct lipolysis, resulting in superior efficacy for treating obesity and non-alcoholic fatty liver disease (MASH/NASH).

Mechanism of action

GLP-1 action: Potently inhibits appetite, reducing caloric intake and improving insulin resistance.
Glucagon action: Promotes direct degradation of triglycerides in adipose tissue and drastically increases energy expenditure (thermogenesis).
The synergy of burning more calories and eating less creates a forced and insurmountable caloric deficit.

Uses & indications

Primary treatment of NASH/MASH: Shows massive clearance of liver fat, preventing fibrosis.
Extreme obesity: As an intervention prior to surgery.

Effects

Body weight reduction of nearly 19% in Phase 2 trials at 46 weeks. The impact on fatty liver reduction is currently the highest measured pharmacologically.

Considerations & contraindications

Gastrointestinal safety profile similar to Semaglutide (transient nausea).
Requires slow titration over several months.

Regulatory approval

In Phase 3 trials (SYNCHRONIZE Program).

Dosage

Escalation phases from 0.6mg weekly to maintenance doses of 4.8mg weekly, depending on tolerance.

Storage

Refrigerated at 2-8°C.

Technical data

Regulatory status Under research

Molecular weight 4638.1 Da

Half-life Administración semanal

Administration routes Subcutánea semanal